Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The fusion glycoprotein F0 is a viral surface protein responsible for mediating the entry of viruses, such as Human respiratory syncytial virus (HRSV) and Nipah virus (NiV), into host cells. It is synthesized as an inactive precursor that is subsequently cleaved into F1 and F2 subunits, forming a trimeric complex. This complex undergoes conformational changes to facilitate fusion between the viral envelope and the host cell membrane. It is a major target for neutralizing antibodies and vaccine development.
Neutralization of fusion activity via antibody binding or inhibition of conformational change.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fusion glycoprotein F0.